The HEBE study is a multicentre trial that randomised 200 patients with large first acute myocardial infarction ( AMI ) treated with primary percutaneous coronary intervention to either intracoronary infusion of bone marrow mononuclear cells ( BMMCs ) ( n = 69 ) , peripheral blood mononuclear cells ( PBMCs ) ( n = 66 ) or standard therapy ( n = 65 ) .